American BioScience, Inc.
560 Bradley Parkway
Blauvelt
New York
10913
United States
Tel: 888-884-7770
Website: http://www.americanbiosciences.com/
12 articles about American BioScience, Inc.
-
American Pharmaceutical Partners And American BioScience, Inc. Complete Merger To Form Abraxis BioScience, Inc.
4/19/2006
-
American BioScience, Inc. And American Pharmaceutical Partners To Present Six Abstracts On Applications Of Nanoparticle Albumin Bound (nab(TM)) Tumor Targeting Technology At The 97th American Association for Cancer Research Annual Meeting
4/5/2006
-
American Pharmaceutical Partners And American BioScience, Inc. Announce Senior Management Team Of Abraxis BioScience, Inc.
2/14/2006
-
Patrick Soon-Shiong, M.D., CEO Of American BioScience, Inc. And Larry Norton, M.D., Of Memorial Sloan-Kettering Cancer Center Receive Gilda's Club New York City Award For The Advancement Of Cancer Medicine
1/30/2006
-
Carlo Montagner To Be Named President Of Abraxis Oncology Upon Completion Of Merger of APP and ABI
1/25/2006
-
American BioScience, Inc. Names Barry Flannelly, Pharm.D, MBA, As Global Vice President Sales And Marketing - Abraxis Oncology
12/21/2005
-
American Pharmaceutical Partners To Merge With Parent Company, American BioScience, Inc., Creating Abraxis Bioscience
11/28/2005
-
Taiho Pharmaceutical Licensed To Develop And Sell ABRAXANE Anti-Cancer Agent By American BioScience, Inc.
11/21/2005
-
American BioScience, Inc. Licenses ABRAXANE(TM) To Taiho Pharmaceutical, One Of The Largest Oncology Companies In Japan
11/16/2005
-
American BioScience, Inc. Release: Key To Improved Chemotherapy Response To ABRAXANE(TM) Validated By Clinical Data
11/3/2005
-
American Pharmaceutical Partners And American BioScience, Inc. Release: Phase I Study Of High Dose Weekly ABRAXANE(TM) Published In Journal Of Clinical Oncology: Responses Achieved In Patients With Taxol(R) Refractory Ovarian Cancer And Lung Cancer
11/1/2005
-
American Pharmaceutical Partners And American BioScience, Inc. Release: Journal Of Clinical Oncology Publishes Pivotal Phase III Study Reporting Superior Response Rate Of ABRAXANE(TM) Compared With Taxol(R) In Women With Metastatic Breast Cancer
11/1/2005